LENZ THERAPEUTICS, INC. Advertising Expense
LENZ THERAPEUTICS, INC. (LENZ) reported Advertising Expense of $11.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AdvertisingExpense · last filed 2026-08-11
- LENZ THERAPEUTICS, INC. advertising expense for the quarter ending 2026-06-30 was $11.40M.
- LENZ THERAPEUTICS, INC. advertising expense for the quarter ending 2026-03-31 was $14.20M.
- LENZ THERAPEUTICS, INC. advertising expense for the quarter ending 2025-12-31 was $6.30M.
- LENZ THERAPEUTICS, INC. advertising expense for the quarter ending 2025-09-30 was $1.70M.
- LENZ THERAPEUTICS, INC. advertising expense for fiscal 2025 was $8.00M.
- LENZ THERAPEUTICS, INC. advertising expense for fiscal 2024 was $0.00.
| Period end | Advertising Expense 3 month | Advertising Expense 6 month | Advertising Expense 9 month | Advertising Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.40M 10-Q · filed 2026-08-11 | $25.60M 10-Q · filed 2026-08-11 | $31.90M derived: sum of 3 quarters · filed 2026-08-11 | $33.60M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $14.20M 10-Q · filed 2026-05-11 | $20.50M derived: sum of 2 quarters · filed 2026-05-11 | $22.20M derived: sum of 3 quarters · filed 2026-05-11 | $22.20M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $6.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $8.00M derived: sum of 2 quarters · filed 2026-03-24 | $8.00M derived: sum of 3 quarters · filed 2026-08-11 | $8.00M 10-K · filed 2026-03-24 |
| 2025-09-30 | $1.70M 10-Q · filed 2025-11-05 | $1.70M derived: sum of 2 quarters · filed 2026-08-11 | $1.70M 10-Q · filed 2025-11-05 | $1.70M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | $0.00 derived: sum of 3 quarters · filed 2026-08-11 | $0.00 derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-11 | $0.00 derived: sum of 2 quarters · filed 2026-05-11 | $0.00 derived: sum of 3 quarters · filed 2026-05-11 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $0.00 derived: sum of 2 quarters · filed 2026-03-24 | $0.00 10-K · filed 2026-03-24 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |